BRIDGEWATER, N.J. , Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
— First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage —
—Total Company Revenues of $425.5 Million for the Second Quarter of 2026—
Barchart Research What to Expect from INSM Earnings INSM Generated August 5, 2026 Current Price $99.02 EPS Estimate $$-0.69 Consensus Rating Strong Buy Average Move 7.20% Can Insmed's Revenue Growth Mask...
BRIDGEWATER, N.J. , July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
After a second quarter that saw the index rally around 15%, following a first quarter in which it lost more than 4%, the playing field has been left with a scattered group of winners and losers.
BRIDGEWATER, N.J. , June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte has rallied the healthcare sector over the past year, and analysts remain moderately optimistic about its prospects.
/The%20CoreWeave%20logo%20displayed%20on%20a%20smartphone%20screen_%20Image%20by%20Robert%20Way%20via%20Shutterstock_.jpg)
CoreWeave stock has been included in the illustrious Nasdaq 100 club starting June 22.